Squarepoint’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $27.7M | Sell |
52,884
-22,050
| -29% | -$10.5M | 0.03% | 552 |
|
|
2025
Q4 | $43.6M | Buy |
74,934
+44,998
| +150% | +$23M | 0.05% | 453 |
|
|
2025
Q3 | $13.7M | Buy |
29,936
+25,554
| +583% | +$9.53M | 0.01% | 932 |
|
|
2025
Q2 | $1.33M | Buy |
4,382
+2,734
| +166% | +$815K | ﹤0.01% | 2418 |
|
|
2025
Q1 | $546K | Buy |
1,648
+100
| +6% | +$32.9K | ﹤0.01% | 3212 |
|
|
2024
Q4 | $478K | Buy |
+1,548
| New | +$435K | ﹤0.01% | 3763 |
|
|
2024
Q3 | – | Sell |
-5,170
| Closed | -$1.45M | – | 4465 |
|
|
2024
Q2 | $1.45M | Buy |
+5,170
| New | +$1.23M | ﹤0.01% | 2290 |
|
|
2023
Q1 | – | Sell |
-2,932
| Closed | -$851K | – | 3550 |
|
|
2022
Q4 | $851K | Buy |
+2,932
| New | +$287K | ﹤0.01% | 1932 |
|
|
2022
Q3 | – | Sell |
-4,074
| Closed | -$292K | – | 3241 |
|
|
2022
Q2 | $292K | Buy |
+4,074
| New | +$299K | ﹤0.01% | 2301 |
|
|
2022
Q1 | – | Sell |
-22,827
| Closed | -$1.93M | – | 3253 |
|
|
2021
Q4 | $1.93M | Sell |
22,827
-12,288
| -35% | -$1.01M | 0.01% | 1288 |
|
|
2021
Q3 | $2.8M | Buy |
35,115
+2,528
| +8% | +$218K | 0.01% | 1039 |
|
|
2021
Q2 | $3.17M | Buy |
32,587
+13,123
| +67% | +$1.55M | 0.01% | 940 |
|
|
2021
Q1 | $2.28M | Buy |
19,464
+16,352
| +525% | +$1.91M | 0.01% | 994 |
|
|
2020
Q4 | $346K | Sell |
3,112
-1,641
| -35% | -$201K | ﹤0.01% | 2101 |
|
|
2020
Q3 | $564K | Buy |
4,753
+1,763
| +59% | +$191K | 0.01% | 1351 |
|
|
2020
Q2 | $339K | Buy |
+2,990
| New | +$294K | 0.01% | 1531 |
|
|
2020
Q1 | – | Sell |
-21,301
| Closed | -$1.94M | – | 2258 |
|
|
2019
Q4 | $1.94M | Buy |
21,301
+17,409
| +447% | +$1.69M | 0.01% | 928 |
|
|
2019
Q3 | $336K | Buy |
+3,892
| New | +$365K | ﹤0.01% | 1840 |
|
|
2019
Q2 | – | Sell |
-2,300
| Closed | -$288K | – | 2556 |
|
|
2019
Q1 | $288K | Sell |
2,300
-172
| -7% | -$21.4K | ﹤0.01% | 1794 |
|
|
2018
Q4 | $279K | Sell |
2,472
-1,579
| -39% | -$244K | ﹤0.01% | 1536 |
|
|
2018
Q3 | $867K | Buy |
4,051
+2,451
| +153% | +$615K | 0.01% | 1057 |
|
|
2018
Q2 | $448K | Sell |
1,600
-2,192
| -58% | -$385K | 0.01% | 1225 |
|
|
2018
Q1 | $443K | Sell |
3,792
-133
| -3% | -$16.4K | 0.01% | 1134 |
|
|
2017
Q4 | $360K | Buy |
+3,925
| New | +$224K | 0.01% | 1390 |
|
|
2016
Q3 | – | Sell |
-1,551
| Closed | -$14K | – | 1157 |
|
|
2016
Q2 | $14K | Buy |
+1,551
| New | +$18.6K | ﹤0.01% | 1058 |
|
|
2016
Q1 | – | Sell |
-1,623
| Closed | -$20K | – | 1331 |
|
|
2015
Q4 | $20K | Buy |
+1,623
| New | +$44.5K | ﹤0.01% | 1207 |
|
Other funds holding MDGL
BBA
RI
ACA
PC
VPM
VCM
Squarepoint's MDGL Position: Q1 2026 in Review
Squarepoint reduced its Madrigal Pharmaceuticals (MDGL) stake by 29% in Q1 2026, selling an estimated $10.5M and leaving 52,884 shares worth $27.7M. The position accounts for 0.03% of the portfolio, ranked #552.
Squarepoint first reported a position in MDGL in Q4 2015 and has held it in 26 quarters since. The position peaked at $43.6M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.
- Squarepoint held 52,884 shares of Madrigal Pharmaceuticals worth $27.7M as of Q1 2026.
- Squarepoint sold 22,050 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $10.5M.
- Madrigal Pharmaceuticals made up 0.03% of Squarepoint's portfolio in Q1 2026, its #552 holding.
- Squarepoint first reported a position in Madrigal Pharmaceuticals in Q4 2015 and has held it in 26 quarters since.
- Squarepoint's Madrigal Pharmaceuticals position peaked at $43.6M in Q4 2025.
- 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.